Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

strative expenses. As of June 30, 2013, Orexigen had $55.8 million in cash and cash equivalents and an additional $40.2 million in marketable securities, for a total of $96.0 million.

Product candidates: Contrave (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double-blind, randomized, placebo-controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the independent Data Monitoring Committee (DMC) has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated major adverse cardiovascular events (MACE). Orexigen enrolled into the Light Study a patient population that the company predicted would have an annualized MACE rate between 1% and 2%. Orexigen is preparing to be ready to conduct the interim analysis and resubmit the Contrave NDA in the remaining months of 2013. Orexigen has licensed North American commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.

Empatic™, a fixed dose combination of bupropion SR and zonisamide SR, for the treatment of obesity: In a series of discussions with the FDA on the continued development of Empatic, the FDA stated that Phase 3 data for Empatic may be sufficient to support submission of an NDA without data from a cardiovascular outcomes trial. The FDA indicated that as long as the placebo-subtracted changes in body weight, blood pressure
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Jan. 27, 2012 Neurodevice firm ... Series B investment round led by ... 2011, and secured non-dilutive funding of ... million Innovation Ohio loan and a ...
... GAITHERSBURG, Md., Jan. 27, 2012 GenVec, Inc. (Nasdaq: ... proprietary technologies to create superior therapeutics and vaccines, today ... License Agreement with Novartis (NYSE: NVS).  Under the extension, ... to support its hearing loss and balance disorders program. ...
Cached Medicine Technology:Neurodevice Firm Checkpoint Surgical Raises $3M 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 3
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
... its spa/gourmet green tea at the Las Vegas IECSC, ... the,International Esthetics, Cosmetics & Spa Conference (IECSC) in Las ... will feature one,product unique for its simplicity: green tea. ... Shinwa, an all-natural, organic,green Japanese karigane tea, at the ...
... - SXC Health Solutions, Corp.,("SXC" or the "Company") ... provider of,technology and pharmacy benefits management services, announces ... awarded a,three-year $35 million Pharmacy Benefits Manager (PBM) ... ("TennCare")., Under terms of the proposed agreement, ...
... 23 , - Special Library Association (SLA) ... Anniversary of SLA and Honor Two,Lifetimes of Achievement, ... John,and Jean Piety on being this year,s recipients ... of the Year Award. Mr.,and Mrs. Piety,s contributions ...
... MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC STATUS INCREASES ... with low socioeconomic status (SES) have more advanced cancers at ... of dying in the five years following cancer diagnosis, according ... the August 1, 2008 issue of CANCER , a ...
... women are struggling with the health fallout caused by a ... -- Most women don,t need a survey to tell them ... feel too sluggish to make it through the day with ... single moms, empty-nesters or grandmothers, many -- if not most ...
... (formerly,Diagnostic Ultrasound Corp.), the maker of BladderScan(R) bladder ... selection, for the second year in a row, ... in Washington State by Washington CEO Magazine., ... as the 4th "Best Company To Work For" ...
Cached Medicine News:Health News:Health and Beauty Come Full Circle: Chado-En Brings Full Benefit of Japanese Green Tea to Spas 2Health News:SXC Health Solutions announces three-year $35 million PBM contract with the State of Tennessee 2Health News:John & Jean Piety Named SLA Engineering Librarians of the Year 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Verathon Inc., Recognized, Second Year Running, as Outstanding Workplace in Washington State by Washington CEO Magazine 2
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
... ConTack Labral Anchor is an L-PLA ... for soft tissue reattachment to bone. ... the bony contour of the glenoid, ... Radial Osteo Compression (ROC) design to ...
... can be used for open or arthroscopic ... a sterile disposable inserter. The unique deployment ... insertion of the anchor into bone. ... allows for the two pre-threaded sutures to ...
... TACIT Threaded Anchor and ... in craniofacial and hand ... secure tissue reattachment and ... The small size facilitates ...
Medicine Products: